A Study of IMC-TR1 in Participants With Advanced Solid Tumors

Phase 1 Completed 14 enrolled Eli Lilly and Company

SequentialOpen-labelTreatment

Summary

A study to evaluate the safety and tolerability of anti-TGFβRII monoclonal antibody (IMC-TR1) in participants with advanced solid tumors, as well as gather evidence of anti-tumor activity.

Timeline

Start: 2012-07
Primary completion: 2014-10
Completion: 2014-10

Publications

Tolcher AW, Berlin JD, Cosaert J, Kauh J, Chan E, Piha-Paul SA, Amaya A, Tang S, Driscoll K, Kimbung R, Kambhampati SR, Gueorguieva I, Hong DS. A phase 1 study of anti-TGFbeta receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2017 Apr;79(4):673-680. doi: 10.1007/s00280-017-3245-5. Epub 2017 Mar 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IMC-TR1	Unknown	1.25 mg/kg	Intravenous
Subject	IMC-TR1	Unknown	12.5 mg	Intravenous
Subject	IMC-TR1	Unknown	25 mg	Intravenous
Subject	IMC-TR1	Unknown	800 mg	Intravenous
Subject	IMC-TR1	Unknown	1600 mg	Intravenous

A Study of IMC-TR1 in Participants With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications